FDA reviewers concur with Aerie on Rhopressa's efficacy

Aerie Pharmaceuticals Inc. (NASDAQ:AERI) gained $8.95 (16%) to $64.30 on Wednesday after FDA released briefing documents ahead of an advisory committee meeting to discuss an NDA for Rhopressa netarsudil 0.02%. Reviewers said they concurred with Aerie's "'overall efficacy conclusion" that Rhopressa reduces elevated intraocular pressure (IOP) in patients with glaucoma and ocular hypertension.

FDA's Dermatologic and Ophthalmologic Drugs Advisory Committee is due to meet Friday to discuss an NDA for Rhopressa, a dual inhibitor of Rho kinase and norepinephrine transporter. Its PDUFA date is Feb. 28, 2018...